Progenics Pharmaceuticals Reports Mixed Q1 Results

Progenics Pharmaceuticals (PGNX) up 1% as Q1 net loss meets Street expectations and revenue falls short. 

PGNX reported a net loss of $9.3 million, down from $11.3 million a year prior. Net loss per share was $0.15, down from $0.22 per share a year prior. 

Total revenue was $1.8 million, down from $2.2 million a year prior. 

The Street expected a loss of $0.15 per share on revenue of $3.4 million, according to Capital IQ estimates. 

PGNX trades in a 52-week range of $3.20 to $7.45.